Ian Roberts


Ian Roberts graduated in chemical engineering and obtained a PhD in process engineering from the University of Wales, Great Britain. From 1997 through 2009, he held various management positions at Nestlé, acting among other things as internal Management consultant at Swiss headquarters, as Director of innovation for Nestlé Mexico, and as Director of the chocolate centre of excellence in Switzerland. He has been Chief Technology Officer at Bühler since 2010. Together with Friedrich von Bohlen, Ian Roberts co-chairs the Evaluation Board of Wyss Zurich.

Friedrich von Bohlen

von Bohlen

Friedrich von Bohlen is managing partner at dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp. He is Chairman of the board of the following companies: Apogenix AG, CureVac AG, Molecular Health GmbH and Novaliq GmbH. Friedrich von Bohlen has more than 10 years of entrepreneurial experience in the Life Sciences. As former CEO of Lion Bioscience AG, he led Lion's IPO in 2000 at 'Neuer Markt', Frankfurt and at Nasdaq, New York. In addition to that, he has been awarded numerous prizes, including the German Entrepreneur of the Year prize by Ernst & Young, SAP and Manager Magazin. Friedrich von Bohlen holds a "diplom" in biochemistry from the University of Zurich and a PhD in neurobiology from ETH Zurich. Together with Ian Roberts, Friedrich von Bohlen co-chairs the Evaluation Board of Wyss Zurich. 

Wolfram Burgard


Wolfram Burgard is professor of computer science at the University of Freiburg and head of the research lab for Autonomous Intelligent Systems. His areas of interest lie in artificial intelligence and mobile robots. His research mainly focuses on the development of robust and adaptive techniques for state estimation and control. Over the past years, his group has developed a series of innovative probabilistic techniques for robot navigation and control. They cover different aspects such as localization, map-building, SLAM, path-planning, exploration, and several other aspects. In his previous position from 1996 to 1999 at the University of Bonn, he was head of the research lab for Autonomous Mobile Systems. His group produced several robots that autonomously operated in trade shows and Museums around the world. In 2008, they developed an approach that allowed a car to autonomously navigate through a complex parking garage and park itself. In 2012, they developed the robot Obelix that autonomously navigated like a pedestrian from the campus of the Faculty of Engineering to the city center of Freiburg. Wolfram Burgard has coauthored over 250 publications in robotic and artificial intelligence. In 2008, he was a recipient of a European Coordinating Committee for Artificial Intelligence (ECCAI) fellowship and in 2009 of the Association for the Advancement of Artificial Intelligence (AAAI) fellowship. In 2009, he also received the Gottfried Wilhelm Leibniz Prize, the most prestigious German research award. In 2010, he earned an Advanced Grant of the European Research Council. Since 2012, he is the coordinator of the Cluster of Excellence BrainLinks-BrainTools funded by the German Research Foundation.

Robert Frigg


Robert Frigg has been an active medical device developer and innovator for 35 years. He started his career in 1978 at the Lab for Experimental Surgery in Davos, and became Chief Technology Officer (CTO) of Synthes Inc., a global leader in orthopedics. During his time as a developer in industry he supported and advised many research projects at Universities and Hospitals for which he has received multiple awards. Since 2013, Robert Frigg manages a development team at Startech Engineering AG and supports start-up projects and innovation at several universities. This includes the Balgrist Campus in Zurich, the ie Lab at ETH Zürich, the Empa, the Institute for Clinical Innovation at the University of Salzburg Medical School and the Institute of Health and Biomedical Innovation at the Queensland University of Technology in Brisbane. 

Felix Mayer


Felix Mayer is entrepreneur. He studied Physics at the ETH Zurich and holds a PhD in the field of Microsensors. In 1998, Felix Mayer started his own company Sensirion AG as a spin-off of the ETH. For 18 years, he - together with Moritz Lechner - managed Sensirion as Co-Founder and Co-CEO. In July 2016 they both handed over their CEO function to the next generation by stepping down from their operational management duties. In their new role as active Co-Chairmen of the Board they now focus on strategic product innovations for new markets. Since its foundation, Sensirion has grown to over 600 employees and nowadays is one of the leading sensor companies. Felix Mayer is a member of the board in various other companies and advocates the start-up entrepreneurship in Switzerland. He has received multiple awards.

Hans Christoph Tanner


Chris Tanner is a member of the executive management of Cosmo Pharmaceuticals NV (SIX:COPN), a specialty pharmaceutical company in Gastrointestinal Disorders and Endoscopic Procedures and Cassiopea SpA (SIX:SKIN), a clinical-stage specialty pharmaceutical company in dermatology. He is a member of the board of DKSG AG (SIX:DKSH), Private Equity Holding AG (SIX:PEHN), Joimax GmbH, and Qvanteq AG. Chris Tanner was at UBS from 1977 to 1998. He was a co-founder of the newspaper group 20 Minutes in 1999, a co-investor in Plus Endoprothetik AG in 2001, and after raising the financing for Cosmo Pharmaceuticals in 2005, joined it in 2006 and brought it public in 2007. In 2015 he led the spin-off of Cassiopea SpA from Cosmo Pharmaceuticals. Chris Tanner has a diploma (Lic Oec) in macroeconomics from the University of St. Gallen and a PhD on steering migration in developing countries from the University of St. Gallen.

Brigitte von Rechenberg

von Rechenberg

Brigitte von Rechenberg is Professor of experimental veterinary surgery at the Vetsuisse Faculty of Zurich. She is the founder and head of the Musculoskeletal Research Unit (MSRU) as well as the head of the Steering Committee of the official Competence Center of Applied Biotechnology and Molecular Medicine (CABMM). Her own research focuses on bone and cartilage remodeling and regeneration. Trained as a Board Certified small animal surgeon (ECVS) she is specialized in experimental surgery and preclinical animal studies and her laboratory is the only officially accredited GLP facility for large animal and small laboratory rodents studies at a University in Europe. From 2014 to 2018 Brigitte von Rechenberg was the first female Dean of the Vetsuisse Faculty Zurich.